U.S. RESEARCH ROUNDUP- BlackRock, Blueprint Medicines, MRC Global

Nu Skin Enterprises

08/07/2022 08:09

July 8 (Reuters) - Wall Street securities analysts revised their ratings and price targets
on several U.S.-listed companies, including BlackRock, Blueprint Medicines and MRC Global on
Friday. 
    
    HIGHLIGHTS
     * BlackRock Inc  BLK.N : JP Morgan cuts target price to $729 from $902
     * Blueprint Medicines Corp  BPMC.O : Oppenheimer initiates with outperform rating 
     * MRC Global Inc  MRC.N : Benchmark initiates with buy rating and $14 target price
        
Following is a summary of research actions on U.S. companies reported by Reuters on Friday.
Stock entries are in alphabetical order. 
    
     * Aprea Therapeutics Inc  APRE.O : Wedbush initiates with outperform rating and $3 PT
     * Arcus Biosciences Inc  RCUS.N : Truist Securities cuts price target to $50 from $77
     * BlackRock Inc  BLK.N : JP Morgan cuts target price to $729 from $902
     * Blueprint Medicines Corp  BPMC.O : Oppenheimer initiates with outperform rating 
     * Blueprint Medicines Corp  BPMC.O : Oppenheimer initiates with $80 target price
     * HF Sinclair Corp  DINO.N : JP Morgan raises target price to $53 from $52
     * Intercept Pharmaceuticals Inc  ICPT.O : Oppenheimer cuts target price to $16 from $19
     * Kalvista Pharmaceuticals Inc  KALV.O : Needham cuts target price to $38 from $42
     * Levi Strauss & Co  LEVI.N : JP Morgan cuts price target to $22 from $27
     * MRC Global Inc  MRC.N : Benchmark initiates with buy rating and $14 target price
     * Nu Skin Enterprises Inc  NUS.N : Jefferie cuts price target to $52 from $60
     * Nurix Therapeutics Inc  NRIX.O : JP Morgan cuts target price to $37 from $46
     * TPG Inc  TPG.O : JP Morgan cuts target price to $31 from $36
     * Tradeweb Markets Inc  TW.O : Credit Suisse cuts target price to $88 from $101
 

 (Compiled by Bengaluru Newsroom)
 ((Diaries@thomsonreuters.com))